

Stanislav Sitkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7339182/publications.pdf>

Version: 2024-02-01

53
papers

382
citations

933447

10
h-index

888059

17
g-index

71
all docs

71
docs citations

71
times ranked

439
citing authors

#	ARTICLE	IF	CITATIONS
1	Magnetic resonance imaging and other medical imaging techniques in the diagnosis of gallstones. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 28-34.	0.4	0
2	Chronic pancreatitis and the intestinal microbiome in adults and children: Not only SIBO but also gut dysbiosis has clinical significance. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2022, , 125-133.	0.4	0
3	Gastrointestinal microbiome and <i>Helicobacter pylori</i> : Eradicate, leave it as it is, or take a personalized benefit-risk approach?. World Journal of Gastroenterology, 2022, 28, 766-774.	3.3	10
4	CE with Cu ²⁺ ions and 2-hydroxypropyl- β -cyclodextrin additives for the investigation of amino acids composition of the culture medium in a cellular model of non-alcoholic fatty liver disease. Journal of Pharmaceutical and Biomedical Analysis, 2022, 213, 114663.	2.8	1
5	Gluten-related disorders: current concept. Part 2. Voprosy Prakticheskoi Pediatrii, 2022, 17, 190-195.	0.2	0
6	Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes. Neurogastroenterology and Motility, 2021, 33, e14038.	3.0	10
7	Bad "Good" Bile Acids and Gut Microbiota Dysbiosis in Inflammatory Bowel Disease: Mice and Humans Are Not the Same. Digestive Diseases and Sciences, 2021, 66, 925-927.	2.3	3
8	Gut Microbiota-Mediated Pleiotropic Effects of Fucose Can Improve Inflammatory Bowel Disease by Modulating Bile Acid Metabolism and Enhancing Propionate Production. Inflammatory Bowel Diseases, 2021, 27, e10-e11.	1.9	7
9	Biliary sludge: pathogenesis, etiology and drug therapy. Terapevticheskii Arkhiv, 2021, 93, 179-186.	0.8	2
10	Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, 1, 4-52.	0.4	63
11	Acceptive Immunity: The Role of Fucosylated Glycans in Human Host-Microbiome Interactions. International Journal of Molecular Sciences, 2021, 22, 3854.	4.1	15
12	Intestinal microbiota and dysbiosis in celiac disease. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2021, 66, 116-122.	0.3	1
13	Management of patients with digestive diseases during the COVID-19 pandemic. Clinical Practice Guidelines by the Russian scientific medical society of internal medicine (RSMSIM) and the Gastroenterological Scientific Society of Russia (2nd edition). Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 5-82.	0.4	6
14	Russian Consensus "Hyperammonemia in Adults" (Version 2021). Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 97-118.	0.4	5
15	Clinical guidelines "Chronic diarrhea in adults". Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 7-67.	0.4	5
16	Modern understanding of adult celiac disease. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 84-95.	0.4	5
17	Acne as a common extraintestinal manifestation of celiac disease. Treatment approaches. Meditsinskiy Sovet, 2021, , 126-135.	0.5	0
18	Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. Eksperimental'naya I Klinicheskaya Gastroenterologiya, 2021, , 5-117.	0.4	15

#	ARTICLE	IF	CITATIONS
19	Cytokine profile and immunological status of patients with ulcerative colitis. <i>Voprosy Prakticheskoi Pediatrii</i> , 2021, 16, 52-62.	0.2	1
20	Gluten-related disorders: current concepts. Part 1. <i>Voprosy Prakticheskoi Pediatrii</i> , 2021, 16, 103-110.	0.2	0
21	<i>Helicobacter pylori</i>. The survival strategy of a commensal symbiont in the <i>Homo sapiens</i> population. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 102-108.	0.4	0
22	Necrotizing enterocolitis: current concepts of etiopathogenesis with an emphasis on microbiome and metabolomics. <i>Voprosy Prakticheskoi Pediatrii</i> , 2021, 16, 98-105.	0.2	2
23	Whole-Genome Sequencing of <i>Lactobacillus helveticus</i> D75 and D76 Confirms Safety and Probiotic Potential. <i>Microorganisms</i> , 2020, 8, 329.	3.6	20
24	Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?. <i>Current Medicinal Chemistry</i> , 2020, 27, 3611-3622.	2.4	6
25	Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2020, , 4-51.	0.4	20
26	Report on the work of the 1st stage of the XXIII Congress of the Scientific Society of Gastroenterologists of Russia (GSSR) (St. Petersburg, June 10-11, 2020). <i>Eksperimental'naya I Klinicheskaya Gastroenterologiya</i> , 2020, , 167-168.	0.4	0
27	The role of bacterial metabolites derived from aromatic amino acids in non-alcoholic fatty liver disease. <i>Al'manah Klinicheskoy Mediciny</i> , 2020, 48, 375-386.	0.3	1
28	Identification of Antihypertensive Tripeptides in the Culture Medium of <i>Lactobacillus helveticus</i> D75 and D76 Strains. , 2020, 61, .		0
29	Clinical Potential of Anti-inflammatory Effects of <i>Faecalibacterium prausnitzii</i> and Butyrate in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e40-e41.	1.9	33
30	FRI-266- <i>Saccharomyces boulardii</i> modulates the colonic microbiota towards a more favourable composition in patients with non-alcoholic fatty liver disease (simple steatosis). <i>Journal of Hepatology</i> , 2019, 70, e511.	3.7	0
31	Altered Sphingolipid Metabolism and its Interaction With the Intestinal Microbiome Is Another Key to the Pathogenesis of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e157-e158.	1.9	2
32	Gut Microbiota as a Host Defender and a Foe: The 2 Faces of Commensal <i>Bacteroides thetaiotaomicron</i> in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e71-e71.	1.9	8
33	P841 Small intestinal bacterial overgrowth in patients with Crohn's disease is not only associated with a more severe disease, but is also marked by dramatic changes in the gut microbiome. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S544-S544.	1.3	0
34	Treatment Options for Patients with Gallstones (Cholelithiasis). <i>Meditinskiy Sovet</i> , 2019, , 44-51.	0.5	3
35	Risk factors for developing diastolic dysfunction in nonalcoholic steatohepatitis. <i>Archiv Euromedica</i> , 2019, 9, 104-105.	0.2	0
36	Functional polymorphism of the serotonin reuptake transporter SLC6A4 gene in various clinical variants of irritable bowel syndrome. <i>Al'manah Klinicheskoy Mediciny</i> , 2019, 47, 496-504.	0.3	1

#	ARTICLE	IF	CITATIONS
37	Crohn's disease with isolated gastric involvement as an example of a rare disease phenotype: a clinical case. <i>Al'manah Klinicheskoy Meditsiny</i> , 2019, 47, 592-602.	0.3	1
38	A proposed treatment algorithm for mild to moderate ulcerative colitis with an emphasis on budesonide foam and mucosal healing. <i>Journal of Gastroenterology</i> , 2018, 53, 799-800.	5.1	4
39	P852 A metabolomics approach to discover biomarkers of chronic intestinal inflammation associated with gut microbiota dysbiosis in ulcerative colitis and Celiac Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S547-S548.	1.3	9
40	Complete Genome Sequences of the Probiotic Lactic Acid Bacteria <i>Lactobacillus helveticus</i> D75 and D76. <i>Genome Announcements</i> , 2018, 6, .	0.8	9
41	How to Increase the Butyrate-producing Capacity of the Gut Microbiome: Do IBD Patients Really Need Butyrate Replacement and Butyrogenic Therapy?. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 881-882.	1.3	12
42	Alterations in Polyunsaturated Fatty Acid Metabolism and Reduced Serum Eicosadienoic Acid Level in Ulcerative Colitis: Is There a Place for Metabolomic Fatty Acid Biomarkers in IBD?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2480-2481.	2.3	9
43	Microbiome, gut dysbiosis and inflammatory bowel disease: That moment when the function is more important than taxonomy. <i>Al'manah Klinicheskoy Meditsiny</i> , 2018, 46, 396-425.	0.3	26
44	Blood serum metabolomic assessment – a perspective diagnostic method for non-alcoholic fatty liver disease in men. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2018, 10, 5-14.	0.2	0
45	Low-molecular-weight components of the metabolome control the proliferative activity in cellular and bacterial cultures. <i>Doklady Biological Sciences</i> , 2017, 472, 8-10.	0.6	4
46	P749. Not only butyrate-producing bacteria but possibly also <i>Bacteroides thetaiotaomicron</i> protects against ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, S489.2-S489.	1.3	1
47	NUTRITIONAL FACTORS OF ANEMIA IN ULCERATIVE COLITIS PATIENTS. <i>Eksperimental'naya i Klinicheskaya Gastroenterologiya</i> , 2016, , 19-25.	0.4	0
48	IDENTIFICATION OF BACTERIOCIN GENES IN PROBIOTIC STRAINS OF LACTIC ACID BACTERIA <i>LACTOBACILLUS ACIDOPHILUS</i> D-75 AND <i>LACTOBACILLUS ACIDOPHILUS</i> D-76. <i>Eksperimental'naya i Klinicheskaya Gastroenterologiya</i> , 2016, , 58-65.	0.4	1
49	METABOLIC DYSBIOSIS OF THE GUT MICROBIOTA AND ITS BIOMARKERS. <i>Eksperimental'naya i Klinicheskaya Gastroenterologiya</i> , 2016, 12, 6-29.	0.4	12
50	FUNCTIONAL FOODS ARE CRITICAL COMPONENTS OF TREATMENT OF METABOLIC DISORDERS IN CELIAC DISEASE. <i>Eksperimental'naya i Klinicheskaya Gastroenterologiya</i> , 2016, 12, 42-49.	0.4	0
51	Metabolomics: the perspective search of methods to overcome infertility. <i>Gynecological Endocrinology</i> , 2015, 31, 79-82.	1.7	11
52	P399 Oral butyrate plus inulin improve serum metabolomic profile and gut microbiota composition in ulcerative colitis and celiac disease. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S232.	1.3	3
53	154 MINIMAL HEPATIC ENCEPHALOPATHY: POSSIBILITIES OF DIETARY FIBERS TREATMENT. <i>Journal of Hepatology</i> , 2012, 56, S67.	3.7	2